CD28 is the second signal a T cell needs before it attacks. Many CAR-T cells carry a piece of CD28 inside them to fire harder, ipilimumab works by stopping CTLA-4 from hogging CD28's partners, and a new bispecific antibody presses CD28 directly on T cells that are already bound to prostate cancer cells. This dossier gathers the 1 product (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
CD28 is constitutively expressed on T cells, and CD80 on antigen-presenting cells is its primary auxiliary signal (UniProt P33681). The bispecific approach costimulates only T cells whose other arm is already engaged with a tumour antigen, here PSMA.
- T cells (constitutive); the costimulatory domain of CD19 CAR-T products
- Prostate cancer (PSMA x CD28 bispecific JNJ-87189401)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →| Modality | Phase 3 |
|---|---|
| Bispecific antibody 1 |
Trials
Evidence ranking →| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Recruiting | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer | - |
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Literature
Preprints →Query for this target: (TITLE:"CD28" OR ABSTRACT:"CD28" OR TITLE:"CD28 molecule" OR ABSTRACT:"CD28 molecule" OR TITLE:"CD28 costimulatory receptor" OR ABSTRACT:"CD28 costimulatory receptor") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD28, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd28.json. Licence CC BY-NC 4.0.